Lexicon Pharmaceuticals, Inc. (LXRX) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $1.0B · $2.27 · 52-week range $0.91–$2.68

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-02-25	DEBBANE RAYMOND	director	2,000	$1.49	$2,980	SEC Form 4
2026-02-23	DEBBANE RAYMOND	director	100,000	$1.47	$147,000	SEC Form 4
2026-02-20	DEBBANE RAYMOND	director	100,000	$1.48	$147,790	SEC Form 4
2026-02-19	DEBBANE RAYMOND	director	50,000	$1.44	$71,965	SEC Form 4
2026-02-18	DEBBANE RAYMOND	director	133,688	$1.32	$176,468	SEC Form 4
2026-02-17	DEBBANE RAYMOND	director	76,857	$1.31	$100,544	SEC Form 4
2026-02-13	DEBBANE RAYMOND	director	57,952	$1.31	$75,877	SEC Form 4
2026-02-02	Invus Global Management, LLC	director, 10 percent owner:	1,538,462	$1.30	$2,000,001	SEC Form 4

Financial health

Altman Z-Score -0.52 · Piotroski F-Score 4/9 · Cash $96M · Debt $62M

ClearOcean signal read

ClearOcean's model currently scores LXRX as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — LXRX Form 4
How ClearOcean reads insider activity

Last updated July 09, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.